Tsumura & Co.
Records under this name other than the patents Tsumura & Co. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 17 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,579,297 | Pharmaceutical composition for application to nail Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,741,358 | Ghrelin production promoter Lapsed on the fee record Ended Jun 3, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 3, 2026 | USPTO record |
| US 8,609,352 | Bioassay method for yokukansan with serotonin receptor Lapsed on the fee record Ended Dec 17, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 17, 2025 | USPTO record |
| US 8,497,092 | Method of bioassaying yokukansan Lapsed on the fee record Ended Jul 30, 2025 · USPTO record | Lapsed on the fee record | Ended Jul 30, 2025 | USPTO record |
| US 8,428,883 | Multi-component medicine evaluation method Lapsed on the fee record Ended Apr 23, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 23, 2025 | USPTO record |
| US 8,420,336 | Method of bioassaying yokukansan Lapsed on the fee record Ended Apr 16, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 16, 2025 | USPTO record |
| US 7,326,427 | Tablet composition containing Kampo medicinal extract and its manufacturing process Term ended Term ended Jul 10, 2023 · USPTO record | Term ended | Term ended Jul 10, 2023 | USPTO record |
| US 7,947,707 | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same Formerly held Lapsed on the fee record Ended May 24, 2019 · USPTO record | Lapsed on the fee record | Ended May 24, 2019 | USPTO record |
| US 6,413,995 | Cinnamamide derivatives and drug compositions containing the same Lapsed on the fee record Ended Jul 2, 2010 · USPTO record | Lapsed on the fee record | Ended Jul 2, 2010 | USPTO record |
| US 6,313,153 | Compositions and methods for treating nephritis and inhibiting TGF -.beta. related conditions using pyridylacrylamide derivatives Formerly held Lapsed on the fee record Ended Nov 6, 2009 · USPTO record | Lapsed on the fee record | Ended Nov 6, 2009 | USPTO record |